Drug Device Combination
Products

The National Medical Products Administration (NMPA) defines drug-device combination products as medical products composed of both drugs and medical devices, integrated into a single entity.

To register a combination product with the NMPA, you must first determine the product’s Primary Mode of Action (PMOA):

Drug-led combination products registration applications must be submitted to the Center for Drug Evaluation (CDE)
Device-led combination products must be submitted to the Center for Medical Device Evaluation (CMDE).

If the device PMOA is unclear, applicants can apply for an attribute definition from the NMPA’s Center for Medical Device Standards Management (CMDSM) before submitting the premarket approval application.

Single entity combination products
Drug products inside delivery device

Joint Evaluation of Drug Device 
Combination Products

During a joint evaluation, the CDE and CMDE collaborate to assess the product's safety, effectiveness, and quality control. Each center issues an evaluation report covering its respective component, and the leading unit consolidates these findings into an overall evaluation report. This report is then submitted to the relevant NMPA department for administrative approval.

For drug-led combination products, the CDE leads the evaluation. If a joint evaluation is required, the application dossier is transferred to the CMDE for synchronized evaluation.

For device-led combination products, the CMDE leads the evaluation. If a joint evaluation is required, the dossier is transferred to the CDE.

During a joint evaluation, the CDE and CMDE collaborate to assess the product's safety, effectiveness, and quality control. Each center issues an evaluation report covering its respective component, and the leading unit consolidates these findings into an overall evaluation report. This report is then submitted to the relevant NMPA department for administrative approval.

Our China Drug-Device Combination Product Services

With expertise in both pharmaceutical and medical device regulations, we assist with the classification, registration and compliance of both drug and device-led combination products.

Our services include:

Regulatory Pathway Assessment

If uncertain, we assist in applying for an attribute definition with the Center for Medical Device Standards Management (CMDSM).
Determine the product’s primary mode of action (PMOA) to classify it as drug-led or device-led.

Registration Strategy Development

Develop a customized regulatory strategy aligned with the requirements of the Center for Drug Evaluation (CDE) or the Center for Medical Device Evaluation (CMDE), depending on the product’s classification.
Coordinate with both centers for joint evaluations as required.

Dossier Preparation & Submission

Ensure that documentation covers both drug and device components, including safety, efficacy, and quality control data including the necessary type testing in China.
Prepare and compile the registration dossier, ensuring compliance with NMPA guidelines.
Submit the application through the NMPA online platform.

Clinical Trial Application (CTA)

Ensure compliance with Good Clinical Practice (GCP) standards for both drug and device components.
Assist in obtaining approval for clinical trials if required.

Communication & Coordination with Regulatory Authorities

Liaise with the CDE and CMDE to facilitate the evaluation process.
Address enquiries and provide additional documentation as requested by regulators.

Post-Approval Compliance

Ensure compliance with post-market surveillance requirements, including pharmacovigilance and medical device vigilance.
Support registration renewals, variations, and amendments.

Request a Proposal from Our Life Sciences Team about Your Combination Product

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide

Learn when local testing is required for medical devices and IVDs in Indonesia, which products are affected, and how testing impacts registration requirements.

August 31, 2026
Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide
An Indonesian male medical professional in profile, wearing dark blue scrubs, a blue surgical cap, safety glasses, a white mask, and a blue-tubed stethoscope, presses a button on a dual-monitor medical control panel in a clinical operating setting.

China Medical Device GMP vs ISO 13485: Key Differences Explained

Understand the key differences between China Medical Device GMP and ISO 13485, including requirements for quality management, suppliers, facilities and documentation.

August 26, 2026
China Medical Device GMP vs ISO 13485: Key Differences Explained
Two Chinese medical device technicians, a woman and a man wearing white lab coats, surgical caps, face masks, and protective gloves, stand side by side in a sterile cleanroom environment.

5-Step Guide to Taiwan Medical Device Classification (TFDA)

How to determine medical device classification in Taiwan: the TFDA catalogue, the 16 categories, Class I-III risk levels, and what to do when no item matches.

August 21, 2026
5-Step Guide to Taiwan Medical Device Classification (TFDA)

Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

Learn when medical device and IVD changes in Indonesia require a notification, variation, or new registration, and how to maintain ongoing regulatory compliance.

August 5, 2026
Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

How Vietnam Medical Device Registration Works (Timelines, Fees, & AR Strategy)

Gain an overview of the medical device registration process in Vietnam with timelines, fees, and Authorized Representative requirements.

August 4, 2026
How Vietnam Medical Device Registration Works (Timelines, Fees, & AR Strategy)

Understanding the ASEAN Medical Device Market: Comparing 6 Strategic Markets

Explore the medical device market opportunities, regulations, and registration pathways across Malaysia, Singapore, Vietnam, and other key ASEAN countries.

August 4, 2026
Understanding the ASEAN Medical Device Market: Comparing 6 Strategic Markets
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

Pharmaceutical Development & Strategy Consulting

We assess your product’s market viability and identify development gaps to enhance readiness. We create tailored regulatory and clinical strategies aligned with Chinese health authority requirements, ensuring clear and compliant communication for streamlined approval.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Latest Insights

View More

Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

Circular No. 2/2026 revises prohibited, restricted, colorant, and preservative requirements for cosmetics marketed in Malaysia.

August 20, 2026
Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?

Brands must audit ingredients, suppliers and packaging before January 2028 to ensure compliance with GB 7916-2026.

August 18, 2026
China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?
Scientist in clean modern room inspects cosmetics.

China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Companies can benefit from expanded toxicology data exemptions, simplified cosmetics registration procedures, and more efficient compliance pathways

August 18, 2026
China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories

August 18, 2026
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed

New NCI rules reduce administrative burden, streamline dossiers, and expand opportunities to reuse existing safety data.

August 18, 2026
China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed
This stock photo features a close-up, high-angle shot focusing on a skincare product arrangement set against a light-colored, wood-grain surface.

NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria

Review China's new draft standards for cosmetic cheilitis and contact urticaria before the August 15, 2026, consultation deadline.

August 18, 2026
NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria
Previous
Previous

Get in Touch with Our Life Sciences Team

And discover how we can support you in achieving approval for your drug-device combination product in China.

Request Proposal